Evidence map›Paper›PMID 41823171›Full record

ArticleFuture oncology (London, England)2026

The integrated 31-gene expression profile test identifies low-risk patients with cutaneous melanoma who can forego the SLNB procedure: results from a prospective, multicenter trial.

Timothy Beard, J Michael Guenther, Stanley P Leong, Maki Yamamoto, Samuel Dierks, Brenda Sickle-Santanello, Andrew Ward, Mark Cripe, Parth Shah, Shawn Young

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Timothy BeardSummit Medical Group, Bend, OR, USA.
J Michael GuentherSt Elizabeth Physicians General & Vascular Surgery, Edgewood, KY, USA.
Stanley P LeongCenter for Melanoma Research and Treatment, California Pacific Medical Center and Research Institute, San Francisco, CA, USA.
Maki YamamotoSchool of Medicine, University of California-Irvine, Orange, CA, USA.
Samuel DierksResearch & Development, Castle Biosciences, Friendswood, TX, USA.
Brenda Sickle-SantanelloSurgical Oncology Associates of Columbus, Columbus, OH, USA.
Andrew WardCollege of Nursing, University of Tennessee Medical Center, Knoxville, TN, USA.
Mark CripeBreast and Cancer Surgery, OhioHealth Physician Group, Columbus, OH, USA.
Parth ShahSurgical Oncology, SurgOne, Denver, CO, USA.
Shawn YoungSurgical Oncology, SurgOne, Denver, CO, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsProspectively confirm use of the integrated 31-gene expression profile test (i31-SLNB) in patients with cutaneous melanoma to predict sentinel lymph node biopsy (SLNB) positivity and assess recurrence rates in those considered low risk by i31-SLNB who did not have an SLNB.

methodsPatients with T1-T4 tumors being considered for SLNB who received 31-gene expression profile (31-GEP) testing in the multi-center, prospective DECIDE study were included (n = 912). Kaplan-Meier analysis was used to estimate recurrence-free survival (RFS).

resultsAmong 430 patients with T1-T4 tumors who had an SLNB, the positivity rate was 2.6% (3/114) in those with <5% i31-SLNB-predicted risk versus 21.4% (28/131) in those with >10% predicted risk. Among those with T1-T2a tumors who had an SLNB (n = 359), the positivity rate was 1.8% (2/111) in those with <5% predicted risk versus 16.7% (12/72) in those with >10% predicted risk. The 3-year RFS rate was 97.8% in patients with i31-SLNB <5% predicted risk.

conclusionsIn this multi-center prospective study, the i31-SLNB accurately predicted SLN positivity, and patients who avoided SLNB based on i31-SLNB results had high RFS. Thus, the i31-SLNB identifies low-risk patients who may consider foregoing the SLNB procedure.

Indexed as

Biomarkers, TumorGene Expression ProfilingMelanomaNeoplasm Recurrence, LocalSentinel Lymph Node BiopsySkin NeoplasmsTranscriptomeAdultAgedAged, 80 and overCutaneous Malignant MelanomaFemaleHumansLymphatic MetastasisMaleMiddle AgedBiomarkers, Tumor31-GEPcutaneous melanomagene expression profilei31-SLNBsentinel lymph node biopsy

Identifiers

PMID41823171
PMCPMC13235228

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.